QBridge AI
↗Mexico City, Mexico
QBridge AI is an AI-first technology company dedicated to the healthcare and life sciences industries. It operates as a core entity within the QBridge Group, which includes QBridge Data-Labs, QBridge Care, and DOT. The company focuses on rectifying clinical research inefficiencies by streamlining, accelerating, and cost-optimizing the R&D lifecycle through 'quantum-level datapoint bridging.'
Headquartered in Mexico with a global strategic vision, QBridge AI aims to deploy seven transformative AI solutions by 2030. Their platform is designed to harmonize AI with human stories in clinical trials, ensuring universal access to high-quality care and driving measurable advancements in life sciences data management and SEO.
CLASSIFICATION
Company Type:Digital Health
Therapeutic Areas:-
Industry:Digital Health
Sub-Industry:Clinical Research AI
SIZE & FINANCIALS
Employees:1-50
Founded:2025
Ownership:private
Status:operating
FUNDING
Stage:Seed
PIPELINE
Stage:Discovery
Lead Drug Stage:N/A (Service/Platform Provider)
Modalities:AI Platform, Data Engineering, Generative AI
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Q BRIDGE Group
Subsidiaries:Q BRIDGE Data-Labs, Q BRIDGE Care, DOT
Key Partnerships:Avant Sante Research Center (Clinical research collaboration)
COMPETITION
Position:Emerging
Competitors:Saama Technologies, Medidata Solutions, Veeva Systems, IQVIA
LEADERSHIP
Key Executives:
Vamsy Mojjada - Founder & CEO
Scientific Founders:Vamsy Mojjada
Board Members:Vamsy Mojjada (Chair)
LINKS
Website:qbridge.ai
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with QBridge AI. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.